Immorta Bio Joins NYU Stern’s Endless Frontier Labs for Life Sciences Acceleration

  • Immorta Bio selected for the 2026–27 Life Sciences cohort of Endless Frontier Labs (EFL) at NYU Stern.
  • EFL provides access to a network of entrepreneurs, scientists, investors, and Stern MBA students.
  • Immorta Bio is developing two therapeutic platforms: SenoMune™ and StemCellRevivify™.
  • The nine-month program begins as Immorta Bio advances from preclinical to clinical-stage development.

Immorta Bio’s selection into NYU Stern’s Endless Frontier Labs underscores the growing emphasis on bridging scientific innovation with commercialization in the biotech sector. The program’s focus on providing access to a robust ecosystem of investors, entrepreneurs, and scientists aligns with the broader trend of startups leveraging academic and business networks to accelerate development. This move could position Immorta Bio as a key player in the scientific longevity space, particularly as it transitions from preclinical to clinical-stage development.

Clinical Development
How Immorta Bio’s entry into human clinical trials will impact its strategic positioning.
Strategic Relationships
Whether the EFL network will accelerate Immorta Bio’s partnerships and funding.
Market Validation
The pace at which Immorta Bio can translate its scientific breakthroughs into commercial success.